Serous Epithelial Ovarian Cancer: Retrospective Analysis of 260 Cases

Authors

  • Sedat Akgöl Department of Gynecologic Oncology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey https://orcid.org/0000-0001-8609-3049
  • Erhan Aktürk Department of Obstetrics and Gynecology, Prof. Dr. Cemil Taşçıoğlu City Hospital, Istanbul, Turkey
  • İpek Yıldız Özaydın Department of Pathology, Health Sciences University, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey
  • Fatma Ölmez Department of Obstetrics and Gynecology, Health Sciences University, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey
  • Sema Karakaş Department of Gynecologic Oncology, Health Sciences University, Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey https://orcid.org/0000-0002-2795-4766
  • Süleyman Cemil Oğlak Department of Obstetrics and Gynecology, Health Sciences University, Gazi Yaşargil Training and Research Hospital, Diyarbakır, Turkey https://orcid.org/0000-0001-7634-3008
  • Adnan Budak Department of Obstetrics and Gynecology, Health Sciences University, Tepecik Training and Research Hospital, Izmir, Turkey
  • Ömer Fatih Ölmez Department of Medical Oncology, Medipol University, Istanbul, Turkey https://orcid.org/0000-0001-7934-7039
  • Mehmet Şükrü Budak Department of Obstetrics and Gynecology, Private Can Hospital, Izmir, Turkey
  • Özgür Akbayır Department of Gynecologic Oncology, Prof. Dr. Cemil Taşçıoğlu City Hospital, Istanbul, Turkey

DOI:

https://doi.org/10.46328/aejog.v3i1.83

Abstract

Objective: To evaluate the outcomes of patients who were followed up and treated for serous epithelial ovarian tumor.

Materials and Methods: This retrospective study included 260 patients who were diagnosed with serous epithelial ovarian cancer, treated and followed up at Kanuni Sultan Suleyman Training and Research Hospital between January 2002 and December 2019.

Results: The mean age of the patients participated in the study was 53.4±11.6 years. Of the patients, 79.7% had advance stage and 82.4% had grade 3 tumors. The rate of complete or optimal surgery was 88.2%, while the rate of suboptimal surgery was 11.2%. While 82% of the patients received adjuvant chemotherapy, 15.7% received neoadjuvant chemotherapy. Of the patients, 80.2% had a Ca 125 value higher than 35. Despite primary cytoreductive surgery and platinum-based adjuvant chemotherapy, the recurrence rate was 66.2%, and the PFS and OS rates were 34.7±41.0 and 50.5±40.0 months, respectively.

Conclusion: The majority of serous epithelial ovarian cancers are diagnosed at an advanced stage. Despite primary situ reductive surgery and subsequent platinum-based chemotherapy, the recurrence rates are quite high.

Downloads

Published

2021-04-03

How to Cite

1.
Akgöl S, Aktürk E, Yıldız Özaydın İpek, Ölmez F, Karakaş S, Oğlak SC, Budak A, Ölmez Ömer F, Budak M Şükrü, Akbayır Özgür. Serous Epithelial Ovarian Cancer: Retrospective Analysis of 260 Cases. Aegean J Obstet Gynecol [Internet]. 2021 Apr. 3 [cited 2021 Apr. 23];3(1):19-21. Available from: https://aejog.com/index.php/aejog/article/view/83

Most read articles by the same author(s)